FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:2522-2524 June 14, 2007 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

In this issue of the Journal, Nissen and Wolski¹ report the results of a meta-analysis of treatment trials of rosiglitazone, as compared either with other therapies for type 2 diabetes or with placebo. Eligible studies included randomized trials that lasted for at least 24 weeks. The prespecified primary end points of interest were myocardial infarction and death from cardiovascular causes. The authors identified 42 eligible studies, many of which were small or short-term trials, that included a total of 158 myocardial infarctions and 61 deaths from cardiovascular causes. They used the Peto method to combine data from the trials. In . . . [Full Text of this Article]

Source Information

From the Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology, and Health Services, University of Washington, and the Center for Health Studies, Group Health, Seattle (B.M.P.); and the Division of Public Health Sciences, Wake Forest University, Winston-Salem, NC (C.D.F.).

This article (10.1056/NEJMe078099) was published at www.nejm.org on May 21, 2007.

This article has been cited by other articles:

• Bakhai, A. (2008). Adipokines--targeting a root cause of cardiometabolic risk. QJM 101: 767-776 [Abstract] [Full Text]  
• Marrie, R. A. (2008). You get what you measure: Evaluating endpoints in MS clinical trials. Neurology 71: 620-621 [Full Text]  
• Lehmann, D. F., Lohray, B. B. (2008). A Lesson in Moderation: Applying Pharmacodynamics to Clarify the Relationship Between Thiazolidinediones and Adverse Vascular Outcomes in Type 2 Diabetes. J Clin Pharmacol 48: 999-1002 [Full Text]  
• Shen, L. Q., Child, A., Weber, G. M., Folkman, J., Aiello, L. P. (2008). Rosiglitazone and Delayed Onset of Proliferative Diabetic Retinopathy. Arch Ophthalmol 126: 793-799 [Abstract] [Full Text]  
• Kuipers, I., van der Harst, P., Navis, G., van Genne, L., Morello, F., van Gilst, W. H., van Veldhuisen, D. J., de Boer, R. A. (2008). Nuclear Hormone Receptors as Regulators of the Renin-Angiotensin-Aldosterone System. Hypertension 51: 1442-1448 [Full Text]  
• Betteridge, D. J., DeFronzo, R. A., Chilton, R. J. (2008). PROactive: time for a critical appraisal. Eur Heart J 29: 969-983 [Abstract] [Full Text]  
• Sanz, J., Moreno, P. R., Fuster, V. (2008). The year in atherothrombosis.. J Am Coll Cardiol 51: 944-955 [Full Text]  
• Duan, S. Z., Usher, M. G., Mortensen, R. M. (2008). Peroxisome Proliferator-Activated Receptor-{gamma}-Mediated Effects in the Vasculature. Circ. Res. 102: 283-294 [Abstract] [Full Text]  
• Dhalla, I. MD, Laupacis, A. MD MSc (2008). Moving from opacity to transparency in pharmaceutical policy. CMAJ 178: 428-431 [Full Text]  
• Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., Zinman, B. (2008). Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: Update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes . Diabetes Care 31: 173-175 [Full Text]  
• Misbin, R. I. (2007). Lessons From the Avandia Controversy: A new paradigm for the development of drugs to treat type 2 diabetes. Diabetes Care 30: 3141-3144 [Full Text]  
• Belloto, R. J Jr (2007). On Statins, Strokes, Meta-Analyses, Competing Risks, and the Onward March of Science. The Annals of Pharmacotherapy 41: 2055-2057 [Abstract] [Full Text]  
• Bloomgarden, Z. T. (2007). The Avandia Debate. Diabetes Care 30: 2401-2408 [Full Text]  
• Bracken, M. B., Mannucci, E., Monami, M., Marchionni, N., Diamond, G. A., Kaul, S., Brett, A. S., Nissen, S. E., Wolski, K., Psaty, B. M., Furberg, C. D. (2007). Rosiglitazone and Cardiovascular Risk. NEJM 357: 937-940 [Full Text]  
• Hirsch, I. B. (2007). TZDs: Where Do We Go From Here?. DOC News 4: 3-3 [Full Text]  
• Ashrafian, H., Frenneaux, M. P., Opie, L. H. (2007). Metabolic Mechanisms in Heart Failure. Circulation 116: 434-448 [Abstract] [Full Text]  
• Psaty, B. M., Furberg, C. D. (2007). The Record on Rosiglitazone and the Risk of Myocardial Infarction. NEJM 357: 67-69 [Full Text]  
• Nathan, D. M. (2007). Rosiglitazone and Cardiotoxicity -- Weighing the Evidence. NEJM 357: 64-66 [Full Text]  
• Drazen, J. M., Morrissey, S., Curfman, G. D. (2007). Rosiglitazone -- Continued Uncertainty about Safety. NEJM 357: 63-64 [Full Text]  
• Home, P. D., Pocock, S. J., Beck-Nielsen, H., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., McMurray, J. J.V., the RECORD Study Group, (2007). Rosiglitazone Evaluated for Cardiovascular Outcomes -- An Interim Analysis. NEJM 357: 28-38 [Abstract] [Full Text]